Karyopharm Therapeutics Inc (NAS:KPTI)
$ 1.06 0.05 (4.9%) Market Cap: 123.45 Mil Enterprise Value: 104.37 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 76/100

Karyopharm Therapeutics Inc at JPMorgan Healthcare Conference Transcript

Jan 11, 2023 / 06:30PM GMT
Release Date Price: $2.96 (+3.14%)
Eric William Joseph
JPMorgan Chase & Co, Research Division - VP & Senior Analyst

Good morning. I'm Eric Joseph, senior biotech analyst with JPMorgan. Our next presenting company is Karyopharm Therapeutics. And presenting on the part of the company is CEO, Richard Paulson, and Chief Medical Officer, Reshma Rangwala. There's a Q&A session after the presentation, just raise your hand, we'll get a mic to you. And for those tuning in via the webcast, feel free to submit questions via the digital conference book, and we'll work them in where appropriate. So with that, Richard?

Richard A. Paulson
Karyopharm Therapeutics Inc. - President, CEO & Director

Good morning, everyone, and thank you, Eric, for hosting us this morning at the JPMorgan Conference. It is invigorating to be able to see everyone in person, and it's a little bit wet to be running outside. We're really pleased to be able to update everybody on the progress that Karyopharm has made in the last year and our plans moving forward to continue to generate value for patients and shareholders

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot